2015 Hemostasis and Thrombosis Research Society/Novo Nordisk Clinical Fellowship Awards in Hemophilia and Rare Bleeding Disorders

2015 Hemostasis and Thrombosis Research Society/Novo Nordisk Clinical Fellowship Awards in Hemophilia and Rare Bleeding Disorders The Hemostasis and Thrombosis Research Society (“HTRS”) and Novo Nordisk Inc. (“Novo Nordisk”) announce the availability of two awards in 2015 for clinical fellowships focused on hemophilia and rare bleeding disorders for one academic year (July 1, 2015 - June 30, 2016). During the fellowship year, awardees are mentored by experienced MDs or DOs working in hemophilia or rare bleeding disorders at established U.S. hemostasis treatment centers (“HTCs”). Eligibility Applicants must be adult or pediatric hematology/oncology MDs or DOs who will have completed a fellowship in an accredited U.S. Hematology, Hematology/Oncology, or Pediatric Hematology/Oncology training program by July 1, 2015. Applicants may be up to 3-years post-fellowship as of July 1, 2015  if the CFA grant provides an opportunity to focus on building a career in hemostasis for those applicants who did not immediately pursue this career track following the completion of their fellowship.   CFA grants are not intended for applicants up to 3-years post-fellowship who have already secured faculty positions in hemostasis. Each applicant must identify a mentor who is an experienced MD or DO working in hemophilia and rare bleeding disorders at a U.S.-based HTC. Both the mentor and the HTC must agree to supervise and h...
Source: ScanGrants feed - Category: Research Authors: Source Type: funding